Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | What’s to come in melanoma at ASCO 2021?

Omid Hamid, MD, The Angeles Clinic and Research Institute, Los Angeles, CA, provides a summary of what to expect in melanoma at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting, including the use of lifileucel, a cryoperserved autologous tumor-infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma, as well as an ongoing study evaluating ipilumumab, nivolumab, and tocilizumab as first-line therapy for patients with advanced melanoma. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.